

Michael A. Levesque — *Curriculum Vitae*

Address: 110 Everden Road
Toronto, Ontario
M6C 3K8
Canada

Telephone: (416) 784-9728

email: Michael.Levesque@UToronto.on.ca

Education

Currently enrolled in the Faculty of Medicine, University of Toronto, “class of 2003”.

Ph.D.	1999	Laboratory Medicine and Pathobiology, University of Toronto
M.Sc.	1996	Clinical Biochemistry, University of Toronto
M.H.Sc.	1992	Clinical Biochemistry, University of Toronto
B.Sc.	1989	Toxicology, University of Toronto

Present Position

Post-Doctoral Fellow, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital
First Year Medical Student, University of Toronto

Awards and Distinctions

Student Travel Grant, Dutkevich Foundation of the University of Toronto (1999)
Student Research Award, Third Place, AACC National Meeting (Chicago IL, 1998)
Postgraduate Medicine, University of Toronto, Edward Christie Stevens Fellowship (1998-1999)
Student Travel Grant, Dutkevich Foundation of the University of Toronto (1998)
Ontario Graduate Scholarship (1998-1999)
University of Toronto Open Fellowship (1998)
Student Travel Grant, National Cancer Institute of Canada (1998)
Student Research Award, Third Place, AACC National Meeting (Chicago IL, 1996)
Student Research Award, Second Place, AACC National Meeting (Anaheim CA, 1995)
Travel Grant, AACC National Meeting (New Orleans LA, 1994)
Young Investigator Award, AACC Upstate New York Section (Corning NY, 1994)
Lorne F. Lambier, QC Scholarship for Cancer Research (1994-1995)
University of Toronto Open Fellowship (1993-1994)
University of Toronto Open Fellowship (1990-1991)

Society Memberships

American Association for the Advancement of Science (1998)
American Association for Cancer Research – Associate Member (1997)
American Association for Clinical Chemistry – Student Associate Member (1994)

Journal Referee

British Journal of Cancer	Clinical Chemistry	Pathology- Research and Practice
The Cancer Journal	Gynecologic Oncology	European Journal of Cancer
Clinical Biochemistry	International Journal of Cancer	Clinica Chimica Acta
Cancer Detection and Prevention	Tumor Biology	

Editorial Activity

Associate Editor, University of Toronto Medical Journal (1999-2000)

Research Grants

Van Slyke Research Grant, American Association for Clinical Chemistry, Principal Investigator (1995-96)

St. Joseph's Health Centre Research Foundation, Assistant (1996-1997)

Cancer Research Society, Assistant (1998-1999)

St. Joseph's Health Centre Research Foundation, Assistant (1998-1999)

Presentations Of Posters At Scientific Meetings

51st Annual Meeting of the American Association for Clinical Chemistry, New Orleans LA July 1999

90th Annual Meeting of the American Association for Cancer Research, Philadelphia PA April 1999

50th Annual Meeting of the American Association for Clinical Chemistry, Chicago IL August 1998

2nd Annual Symposium on Advances in Laboratory Medicine, Toronto, Ontario June 1998

3rd Educational Convention of the European School of Oncology, Turin, Italy, May 1998

34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles CA, May 1998

89th Annual Meeting of the American Association for Cancer Research, New Orleans LA March 1998

49th Annual Meeting of the American Association for Clinical Chemistry, Atlanta GA July 1997

1st Annual Symposium on Advances in Laboratory Medicine, Toronto, Ontario June 1997

16th International Congress of Clinical Chemistry, London UK June 1996

48th Annual Meeting of the American Association for Clinical Chemistry, Chicago IL July 1996

47th Annual Meeting of the American Association for Clinical Chemistry, Anaheim CA July 1995

Canadian Society of Clinical Chemists Annual Meeting, Whistler, British Columbia April 1995

46th Annual Meeting of the American Association for Clinical Chemistry, New Orleans LA July 1994

7th International p53 Workshop, Muskoka, Ontario June 1994

Canadian Society of Clinical Chemists Annual Meeting, Québec, Québec June 1994

Oral Presentations at Scientific Meetings

American Association for Clinical Chemistry Upstate New York Section Spring Meeting, Buffalo NY May 1997

88th Annual Meeting of the American Association for Cancer Research, San Diego CA April 1997

Peters Academy Rounds in Pathology, Toronto, Ontario November 1996

American Association for Clinical Chemistry Upstate New York Section Spring Meeting, Syracuse NY May 1995

7th International p53 Workshop, Muskoka, Ontario June 1994

American Association for Clinical Chemistry Upstate New York Section Spring Meeting, Corning NY May 1994

American Association for Clinical Chemistry Upstate New York Section Spring Meeting, Niagara Falls NY
May 1993

Published Abstracts

1. **Levesque MA**, Diamandis EP, Yu H, Sutherland DJA. Quantitative analysis of prostate specific antigen and mutant p53 protein in breast tumor cytosols: relationships with other prognostic factors. *Clin Biochem* 1994; **27**: 232.
2. Katsaros D, Zola P, Sismondi P, **Levesque M**, Diamandis EP. Prognostic value of p53 protein accumulation in ovarian carcinomas. *Proc Am Assoc Cancer Res* 1994; **35**: 234.
3. **Levesque MA**, Diamandis EP, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Immunofluorometrically quantified p53 protein as a prognostic indicator in ovarian carcinoma. *Clin Chem* 1995; **41**: 5224.
4. **Levesque MA**, Clark G, Diamandis EP. Quantitative analysis of p53 protein in breast carcinoma: relationships to other prognostic factors. *Clin Chem* 1995; **41**: 5224.
5. **Levesque MA**, Clark GM, Diamandis EP. Relationships between mutant p53 protein overexpression and other prognostic indicators in breast cancer. *Clin Biochem* 1995; **28**: 340.
6. **Levesque MA**, Diamandis EP, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Prognostic value of immunofluorometrically quantified p53 protein in ovarian carcinoma. *Clin Biochem* 1995; **28**: 340.
7. Yu H, Diamandis EP, **Levesque MA**, Asa S, Monne M, Croce CM. Prostate specific antigen gene expression in ovarian cancer post-liver transplantation. *Clin Biochem* 1995; **28**: 341.
8. Yu H, **Levesque MA**, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. No associations between IGFBP-3 and p53, or PSA in breast cancer. *Proc Am Assoc Cancer Res* 1996; **37**: 189.
9. Yu H, **Levesque MA**, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. IGF-I, IGF-II, IGFBP-1 and IGFBP-3 as prognostic markers of breast cancer. *Proc Int Congr Endocrinol* 1996; **2**: 756.
10. D'Costa M, **Levesque M**, Tadross L, Diamandis EP. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer. *Clin Chem* 1996; **42**: 262.
11. Yu H, **Levesque MA**, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Associations between PSA and IGF-I, IGF-II, IGFBP-3 in breast cancer. *Clin Chem* 1996; **42**: 264.
12. **Levesque MA**, D'Costa M, Diamandis EP. p53 protein is absent from the serum of patients with lung cancer. *Clin Chem* 1996; **42**: 262.
13. Karumanchiri A, Tsang E, Soleas GJ, Diamandis EP, **Levesque M**, Goldberg DM. Method-dependent bias in the quantification of resveratrol glucosides by high performance liquid chromatography. *Am J Enol Vitic* 1997; **48**:389.
14. **Levesque MA**, Yu H, Clark GM, Diamandis EP. p53 protein accumulation detected by an ELISA technique is a prognostic factor in a large cohort of breast cancer patients. *Proc Am Assoc Cancer Res* 1997; **38**: 255.
15. Yu H, **Levesque MA**, Clark GM, Diamandis EP. Prognostic value of PSA in breast cancer: a large US cohort study. *Cancer Res* 1997; **38**: 437.

16. Zarghami N, **Levesque MA**, D'Costa M, Angelopoulou K, Diamandis EP. Frequency of prostate specific antigen mRNA expression in lung tumors. *Clin Chem* 1997; **43**: S228.
17. Yu H, **Levesque MA**, Khosravi MJ, Diamandis EP, Clark GM. Insulin-like growth factor binding protein 3 and breast cancer recurrence. *Proc Am Assoc Cancer Res* 1998; **39**: 222.
18. **Levesque MA**, Lianidou ES, Angelopoulou K, Yu H, Genta F, Durando A, Massobrio M, Bharaj B, Diamandis EP, Katsaros D. Mutational analysis versus ELISA for the detection of p53 gene abnormalities in ovarian carcinoma. *Proc Am Assoc Cancer Res* 1998; **39**: 230.
19. Katsaros D, **Levesque MA**, Genta F, Durando A, Arisio R, Yu H, Diamandis EP, Massobrio M. Prognostic and predictive implications of p53 and WAF1 expression in ovarian cancer. *Proc Am Assoc Cancer Res* 1998; **39**: 231.
20. Katsaros D, Genta A, Durando A, Danese S, Ricchiardi R, **Levesque M**, Diamandis EP, Massobrio M. Prognostic and predictive value of p53 and WAF1 expression in epithelial ovarian cancer. *Proc Am Assoc Clin Oncol* 1998; **17**: 351.
21. Katsaros D, Genta A, Durando A, Danese S, Ricchiardi R, **Levesque M**, Diamandis EP, Massobrio M. p53 and WAF1 expression in epithelial ovarian cancer: prognostic and predictive implications. *Eur J Cancer* 1998; **34 (Suppl2)**: S22.
22. Scorilas A, Diamandis EP, **Levesque MA**, Khosravi MJ, Giai M, Ponzzone R, Roagna R, Sismondi P, Lopez-Otin C. Pepsinogen C, an independent favorable prognostic factor in node-positive breast cancer patients. *Proc Am Assoc Cancer Res* 1999; **40**: 205.
23. Obiezu CV, Black NH, Magklara A, **Levesque MA**, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. *Proc Am Assoc Cancer Res* 1999; **40**: 378.
24. **Levesque MA**, Yu H, Genta F, Massobrio M, Durando A, Bellino R, Diamandis EP, Katsaros D. Expression of p53 but not WAF1 is a predictor of response to platinum-based chemotherapy in patients with epithelial ovarian cancer. *Proc Am Assoc Cancer Res* 1999; **40**: 382.

Original Research Papers

1. **Levesque MA**, Diamandis EP, Sutherland DJA. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. *Breast Cancer Res Treat* 1994; **30**: 179-195.
2. Yu H, Diamandis EP, **Levesque MA**, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. *J Clin Lab Analysis* 1994; **8**: 480-487.
3. Diamandis EP, **Levesque MA**. Assessment of p53 protein overexpression by non-immunohistochemical methods. *J Pathol* 1994; **175**: 93-95.
4. **Levesque MA**, Yu H, D'Costa M, Diamandis EP. Prostate specific antigen expression by various tumors. *J Clin Lab Analysis* 1995; **9**: 123-128.
5. **Levesque MA**, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. *Cancer* 1995; **75**: 1327-1338.
6. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, **Levesque MA**, Roagna R, Ponzzone R, Sismondi P. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. *Cancer Res* 1995; **55**: 2104-2110.

7. Yu H, Diamandis EP, **Levesque MA**, Asa S, Monne M, Croce CM. Expression of the prostate specific antigen gene by a primary ovarian carcinoma. *Cancer Res* 1995; **55**: 1603-1606
8. **Levesque MA**, Clark GM, Diamandis EP. Immunofluorometric analysis of p53 protein and prostate specific antigen in breast tumours and their association with other prognostic indicators. *Br J Cancer* 1995; **72**: 720-727.
9. Giai M, Yu H, Roagna R, Ponzzone R, Katsaros D, **Levesque MA**, Diamandis EP. Prostate-specific antigen in serum of women with breast cancer. *Br J Cancer* 1995; **72**: 728-731.
10. **Levesque MA**, Yu H, D'Costa M, Tadross L, Diamandis EP. Immunoreactive prostate specific antigen in lung tumors. *J Clin Lab Analysis* 1995; **9**: 375-379.
11. **Levesque MA**, D'Costa M, Angelopoulou K, Diamandis EP. Time-resolved immunofluorometric assay of p53 protein. *Clin Chem* 1995; **41**: 1720-1729.
12. Yu H, Diamandis EP, **Levesque M**, Giai, Roagna R, Ponzzone R, Sismondi P, Monne M, Croce CM. Prostate specific antigen in breast tissue, benign breast disease, and normal breast tissue. *Breast Cancer Res Treat* 1996; **40**: 171-178.
13. Yu H, **Levesque MA**, Khosravi MJ, Papanastasiou-Diamandis A, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. *Br J Cancer* 1996; **74**: 1242-1247.
14. **Levesque MA**, D'Costa M, Diamandis EP. p53 protein is absent from the sera of patients with lung cancer. *Br J Cancer* 1996; **74**: 1434-1440.
15. **Levesque MA**, Tadross L, Diamandis EP, D'Costa M. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. *Am J Clin Pathol* 1997; **107**: 308-316.
16. Zarghami N, **Levesque MA**, D'Costa, Angelopoulou K, Diamandis EP. Frequency of prostate-specific antigen mRNA expression in lung tumors. *Am J Clin Pathol* 1997; **108**:184-190.
17. Angelopoulou K, **Levesque MA**, Katsaros D, Diamandis EP. The exon 5 of the p53 gene is a target for deletions in ovarian cancer. *Clin Chem* 1998; **44**: 72-77.
18. **Levesque MA**, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzzone R, Massobrio M, Sismondi P, Diamandis EP. Immunofluorometrically-determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. *Int J Cancer (Pred. Oncol)* 1998; **79**: 147-152.
19. **Levesque MA**, Yu H, Clark GM, Diamandis EP. ELISA-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. *J Clin Oncol* 1998; **16**: 2641-2650.
20. Yu H, **Levesque MA**, Clark GM, Diamandis EP. Prognostic value of prostate specific antigen for women with breast cancer - a large United States cohort study. *Clin Cancer Res* 1998; **4**: 1489-1497.
21. **Levesque MA**, D'Costa M, Spratt EM, Yaman MM, Diamandis EP. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. *Int J Cancer (Pred Oncol)* 1998; **79**: 494-501.
22. Yu H, **Levesque MA**, Khosravi MJ, Clark GM, Diamandis EP. Insulin-like growth factor binding protein-3 and breast cancer survival. *Int J Cancer (Pred Oncol)* 1998; **79**: 624-628.
23. Lianidou ES, **Levesque MA**, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis EP. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. *Anticancer Res* 1999; **19**: 799-806.

24. Goldberg DM, Tsang E, **Levesque M**, Soleas GJ. Method-dependent bias in the quantitation of resveratrol glucosides by high performance liquid chromatography. *J Liquid Chrom Rel Technol* 1999; **22**: 1843-1855.
25. Yu H, **Levesque MA**, Clark GM, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating the expression of p53 and prostate specific antigen in combination. *Br J Cancer* 1999 (in press).
26. Scorilas A, Diamandis EP, **Levesque MA**, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzzone R, Roagna R, Sismondi P, Lopez-Otin C. Immunofluorometrically-determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. *Clin Cancer Res* 1999; **5**: 1778-1785.
27. Black MH, Magklara A, Obiezu C, **Levesque MA**, Sutherland DJA, Tindall DJ, Young YF, Sauter ER, Diamandis EP. Expression of a prostate-associated protein, human glandular kallikrein (hk2), in breast tumors and in normal breast secretions. *Br J Cancer* 1999 (in press).
28. **Levesque MA**, Katsaros D, Genta F, Massobrio M, Yu H, Pia Mano M, Bellino R, Arisio R, Diamandis EP. Dose-response effect between p53 (but not WAF1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. *Clin Cancer Res* 1999 (in press).
29. **Levesque MA**, D'Costa M, Diamandis EP. p21WAF1 expression determined by a quantitative immunoassay in relation to non-small cell lung cancer aggressiveness. *J Cancer Res Clin Oncol* 1999 (in press).
30. Bharaj B, Scorilas A, Diamandis EP, Gaia M, **Levesque MA**, Hoffman BR. A prevalent polymorphism in the proximal androgen response element of the prostate specific antigen gene and its implications for breast cancer patients. (submitted to *Br J Cancer*).
31. Goldberg DM, Soleas GJ, **Levesque MA**. Moderate alcohol consumption: the gentle face of janus. (submitted to *Clin Biochem*).
32. Katsaros D, Yu H, Massobrio M, **Levesque MA**, Genta F, Fracchioli S, Khosravi MJ, Papanastasiou-Diamandi A, Gordini G, Arisio R, Diamandis EP, Yu H. High IGFBP-3 in epithelial ovarian carcinoma is associated with favorable clinicopathological features and patient survival. (submitted to *Clin Cancer Res*).
33. **Levesque MA**, Bharaj B, Marcuzzi A, Diamandis EP, D'Costa M. Polymorphic length of a CAG (glutamine) repeat within the androgen receptor gene is a predictor of prostate cancer aggressiveness. (manuscript in preparation).
34. Yousef G, Scorilas A, **Levesque MA**, Diamandis EP. Human stratum corneum chymotryptic enzyme (HSCCE), a new member of the human kallikrein-like gene family: structural characterization, mapping, tissue expression, and hormonal regulation. (manuscript in preparation).